Tingting Li1, Yun Shi, Jieyun Yin, Qin Qin, Sheng Wei, Shaofa Nie, Li Liu. 1. Department of Epidemiology and Biostatistics, Key Laboratory of Environment and Health, Ministry of Education and Ministry of Environmental Protection, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.
Abstract
PURPOSE: Hyperlipidaemia has been identified as a risk factor for diabetic nephropathy via exacerbation of glomerular injury through the activation of multiple signaling pathways. This study's aim is to assess the associations between polymorphisms of genes involved in lipid metabolism, such as apolipoprotein E (ApoE), peroxisome proliferator-activated receptor γ (PPARγ), acetyl-CoA carboxylase β (ACACB), and type 2 diabetic nephropathy (T2DN). METHODS: A search of the MEDLINE and Web of Science databases was used to identify relevant studies, and allele or genotype frequencies were pooled using fixed- or random-effects models. RESULTS: Forty-five studies were included in this meta-analysis, consisting of 10,920 type 2 diabetic patients with nephropathy and 16,203 type 2 diabetic patients without nephropathy. The OR for ApoE ε2 versus ε3 was 1.49 (95% CI 1.13-1.95) in T2DN. The progression of T2DN was related to the presence of the ε2 allele and ε2 carrier with ORs of 1.72 (95% CI 1.10-2.69) and 1.78 (95% CI 1.18-2.69), respectively. The rs1801282 C>G variant in PPARγ presented a significant association with decreased T2DN risk, both in the G allele and GC/GG genotype with ORs of 0.77 (95% CI 0.68-0.87) and 0.79 (95% CI 0.69-0.92), respectively. The T allele in rs2268388 within ACACB showed an increased risk for T2DN, exhibiting an OR of 1.35 (95% CI 1.12-1.63). CONCLUSIONS: Our meta-analysis supports that the ApoE ε2 allele and ACACB rs2268388 C>T might act as promotion factors of nephropathy in type 2 diabetes, whereas PPARγ rs1801282 C>G is a promising candidate genetic variation for reducing susceptibility to T2DN.
PURPOSE: Hyperlipidaemia has been identified as a risk factor for diabetic nephropathy via exacerbation of glomerular injury through the activation of multiple signaling pathways. This study's aim is to assess the associations between polymorphisms of genes involved in lipid metabolism, such as apolipoprotein E (ApoE), peroxisome proliferator-activated receptor γ (PPARγ), acetyl-CoA carboxylase β (ACACB), and type 2 diabetic nephropathy (T2DN). METHODS: A search of the MEDLINE and Web of Science databases was used to identify relevant studies, and allele or genotype frequencies were pooled using fixed- or random-effects models. RESULTS: Forty-five studies were included in this meta-analysis, consisting of 10,920 type 2 diabeticpatients with nephropathy and 16,203 type 2 diabeticpatients without nephropathy. The OR for ApoE ε2 versus ε3 was 1.49 (95% CI 1.13-1.95) in T2DN. The progression of T2DN was related to the presence of the ε2 allele and ε2 carrier with ORs of 1.72 (95% CI 1.10-2.69) and 1.78 (95% CI 1.18-2.69), respectively. The rs1801282 C>G variant in PPARγ presented a significant association with decreased T2DN risk, both in the G allele and GC/GG genotype with ORs of 0.77 (95% CI 0.68-0.87) and 0.79 (95% CI 0.69-0.92), respectively. The T allele in rs2268388 within ACACB showed an increased risk for T2DN, exhibiting an OR of 1.35 (95% CI 1.12-1.63). CONCLUSIONS: Our meta-analysis supports that the ApoE ε2 allele and ACACBrs2268388 C>T might act as promotion factors of nephropathy in type 2 diabetes, whereas PPARγ rs1801282 C>G is a promising candidate genetic variation for reducing susceptibility to T2DN.
Authors: M Eto; K Horita; A Morikawa; H Nakata; M Okada; M Saito; M Nomura; A Abiko; Y Iwashima; A Ikoda Journal: Clin Genet Date: 1995-12 Impact factor: 4.438
Authors: S S Deeb; L Fajas; M Nemoto; J Pihlajamäki; L Mykkänen; J Kuusisto; M Laakso; W Fujimoto; J Auwerx Journal: Nat Genet Date: 1998-11 Impact factor: 38.330
Authors: A L Mooyaart; E J J Valk; L A van Es; J A Bruijn; E de Heer; B I Freedman; O M Dekkers; H J Baelde Journal: Diabetologia Date: 2010-12-03 Impact factor: 10.122